Amgen (AMGN.US) Q3 revenue and profit exceed expectations, company raises full-year guidance

According to Jinse Finance APP, Amgen (AMGN.US) released its Q3 2026 financial report after the US stock market closed on November 3: total revenue was $10.365 billion, an increase of 8% year-on-year, higher than the market estimate of about $10.05 billion; non-GAAP earnings per share were $6.45, an increase of 14% year-on-year, significantly higher than the estimated $5.77; GAAP earnings per share were $7.08, an increase of 19% year-on-year.

Growth products continued to expand: UPLIZNA revenue was $451 million, up 191% year-on-year; IMDELLTRA revenue was $406 million, up 128%; TEZSPIRE revenue was $538 million, up 43%; EVENITY revenue was $751 million, up 39%; Repatha revenue was $1.085 billion, up 37%.

Meanwhile, legacy products were significantly impacted by biosimilars: Prolia revenue was $632 million, down 45% year-on-year; XGEVA revenue was $288 million, down 47%; Otezla revenue was $481 million, down 18%. Seventeen products achieved double-digit sales growth during the quarter.

The company also raised its full-year 2026 guidance: total revenue was increased from the previous range of $38.2 billion to $39.4 billion to $38.9 billion to $39.7 billion; non-GAAP earnings per share were lifted from $22.30–$23.50 to $22.90–$23.70.

Despite both performance and guidance beating expectations, Amgen’s share price fell in after-hours trading. As of press time, the stock was down 1.6% after hours.